Company intelligence / Profile preview

JH CisPoly

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

JH CisPoly is a specialized biotechnology company focused on the development and commercialization of molecular diagnostic solutions for early cancer screening and precision medicine. The company leverages its proprietary DNA methylation detection technology to provide non-invasive or minimally invasive testing options for gynecological and urological cancers. Its lead products include kits for cervical and endometrial cancer screening that utilize specific epigenetic biomarkers to improve diagnostic accuracy over traditional cytology. JH CisPoly aims to integrate advanced molecular biology with clinical diagnostics to enhance early detection rates and patient outcomes.

Therapeutic areas: Oncology
Modalities: Molecular diagnosticsPCR-based assaysMethylation detection
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on JH CisPoly.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JH CisPoly.

Explore the full profile